Athersys, Inc. (ATHX) stock declined over -1.47% intraday to trade at $0.24 a share on NASDAQ. The stock opened with a loss of -14.29% at $0.26 and touched an intraday high of $0.27, falling -7.69% against the last close of $0.26. The stock went to a low of $0.24 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue5.51 Million
5Y Sales Change-20.50%
Fiscal Year Ends2021-12-30
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Athersys, Inc. (NASDAQ: ATHX) stock price is $0.24 as of the last check on Friday, July 1. During the trading session, ATHX stock reached the peak price of $0.27 while $0.24 was the lowest point it dropped to.
The NASDAQ listed ATHX is part of Biotechnology industry that operates in the broader Health Care sector. Athersys, Inc. , a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA
Pres, COO, Sec. & Interim CEO
Dr. Eric Jenkins M.D.
Sr. Medical Director & Head of Clinical Operations
Mr. William Lehmann Jr., J.D., M.B.A., MBA
Pres, COO & Sec.
Dr. John J. Harrington Ph.D.
Co-Founder, Chief Scientific Officer, Exec. VP & Director
ATHX stock traded closed the last session at $0.25, which is $-0.01 or -1.47% lower than its previous close of $0.26. ATHX's current trading price is 34.44% lower than its 52-week high of $1.81 where as its distance from 52-week low of 0.18% is -86.63%.
Number of ATHX employees currently stands at -. ATHX operates from 3201 Carnegie Avenue, Cleveland, OH 44115-2634, United States.
Official Webiste of $ATHX is: https://www.athersys.com
ATHX stock volume for the day was 6,608,542 shares while in the previous session number of ATHX shares traded was 2,358,700 . The average number of ATHX shares traded daily for last 3 months was 7.22 Million.
The percentage change in ATHX stock occurred in the recent session was -1.47% while the dollar amount for the price change in ATHX stock was $-0.01.
In the recent session, the day high for ATHX stock was $0.27 while the low for ATHX stock touched on the day was $0.24.
The market value of ATHX currently stands at 65.91 Million with its latest stock price at $0.24 and 244.2 Million of its shares outstanding.